QGEN · Qiagen N.V.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QGEN
this stock
Qiagen N.V.
|
$8.95B | -3.6% | +5.7% | — | 3.6% |
|
TMO
Thermo Fisher Scientific Inc.
|
$240.87B | +12.4% | +14.5% | 35.0 | 1.5% |
|
DHR
Danaher Corp /De/
|
$147.37B | -7.5% | +8.5% | 37.2 | 1.4% |
|
NTRA
Natera, Inc.
|
$53.25B | +61.2% | -2.8% | — | 3.8% |
|
IQV
Iqvia Holdings Inc.
|
$44.71B | +18.2% | +41.6% | 33.3 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QGEN | +2.0% | -3.5% | +10.9% | +0.1% | -3.7% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +2.3% | -3.4% | -9.2% | +0.8% | -15.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.